FDA
-
-
-
-
-
-
-
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
-
-
-
-
-
-
-
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors
-
-
-
-
-
-
-
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit
-
-
-
-
-
-
-
Akari Therapeutcis (AKTX) Granted Nomacopan Orphan Drug Designation in EU for Treatment in Hematopoietic Stem Cell Transplantation
-
-
-
-
-
-
-
Akari Therapeutcis (AKTX) Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation
-
-
-
-
-
-
-
Akari Therapeutcis (AKTX) Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement
-
-
-
-
-
-
-
Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT
-
322,200 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

